Global and Multi-National Prevalence of Fungal Diseases-Estimate Precision
Open accessThe DOI matches its Crossref record; 183 of the 192 references it cites were found in a registry or an index; 48 of the 182 sources its claims cite were checked for support.
Abstract
Fungal diseases kill more than 1.5 million and affect over a billion people. However, they are still a neglected topic by public health authorities even though most deaths from fungal diseases are avoidable. Serious fungal infections occur as a consequence of other health problems including asthma, AIDS, cancer, organ transplantation and corticosteroid therapies. Early accurate diagnosis allows prompt antifungal therapy; however this is often delayed or unavailable leading to death, serious chronic illness or blindness. Recent global estimates have found 3,000,000 cases of chronic pulmonary aspergillosis, ~223,100 cases of cryptococcal meningitis complicating HIV/AIDS, ~700,000 cases of invasive candidiasis, ~500,000 cases of Pneumocystis jirovecii pneumonia, ~250,000 cases of invasive aspergillosis, ~100,000 cases of disseminated histoplasmosis, over 10,000,000 cases of fungal asthma and ~1,000,000 cases of fungal keratitis occur annually. Since 2013, the Leading International Fungal Education (LIFE) portal has facilitated the estimation of the burden of serious fungal infections country by country for over 5.7 billion people (>80% of the world’s population). These studies have shown differences in the global burden between countries, within regions of the same country and between at risk populations. Here we interrogate the accuracy of these fungal infection burden estimates in the 43 published papers within the LIFE initiative.
Overview
CoChat Summary
TL;DR
This review interrogates the accuracy of global and multi-national estimates of serious fungal disease burden generated through the Leading International Fungal Education (LIFE) initiative. It summarizes estimates from 43 published country reports and highlights wide variation, data gaps, and likely underestimation of fungal disease burden.
Key findings
- Recent global estimates include 3,000,000 cases of chronic pulmonary aspergillosis, ~223,100 cases of cryptococcal meningitis complicating HIV/AIDS, ~700,000 cases of invasive candidiasis, ~500,000 cases of *Pneumocystis jirovecii* pneumonia, ~250,000 cases of invasive aspergillosis, ~100,000 cases of disseminated histoplasmosis, over 10,000,000 cases of fungal asthma, and ~1,000,000 cases of fungal keratitis annually.
- Across LIFE country papers, candidaemia burden was 159,253 cases in 39 countries, invasive aspergillosis was 81,927 cases in 40 countries, and *Pneumocystis jirovecii* pneumonia was 133,487 cases in 40 papers; the highest candidaemia prevalence was reported in Pakistan (38,795 cases, 21 per 100,000).
- Chronic pulmonary aspergillosis estimates were highest in India (209,147) and Nigeria (120,753), with an overall incidence of 22 cases per 100,000 (14.2–30.59 95% CI); ABPA was estimated at 3,550,157 cases and SAFS at 4,125,428 cases across 43 countries.
- Tinea capitis was estimated at 21,073,423 cases in just 16 countries, with Nigeria alone accounting for 15,581,400 cases; global recurrent vulvovaginal candidiasis prevalence was estimated at about 134,000,000 cases.
Methods
- Narrative review of 43 published papers within the LIFE initiative, covering >2000 million people (29% of the world population), with the LIFE portal having facilitated estimates for over 5.7 billion people (>80% of the world’s population).
- The paper describes how country-level burden estimates were derived for specific fungal diseases, using published epidemiological data, modelling assumptions, and at-risk population denominators.
- Main analysis is descriptive and comparative: it aggregates country estimates, examines differences by region, country, and at-risk group, and discusses strengths and weaknesses of the estimation methods.
Limitations
- The paper states that a precise estimate of global prevalence and incidence for each fungal infection remains unknown, and data are scanty in most countries, especially in the developing world.
- It states that knowledge is impaired by lack of regular national surveillance, no obligatory reporting of fungal diseases, poor clinician suspicion outside specialised units, poor diagnostic test performance, and few well-designed published studies; estimates are not intended as a substitute for high-quality epidemiological study or comprehensive surveillance.
- It also states that comparisons across countries are difficult because recent local epidemiological data were available for only some countries, data quality varies, not all institutions report infections, and many low- and low-middle-income countries lack blood culture systems; the text makes evident that country estimates rely on heterogeneous assumptions and uniform rates in places, such as 5 per 100,000 for candidaemia when local data were unavailable and 6% for recurrent vulvovaginal candidiasis.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
33 Valid · 8 Not valid · 70 Not checked · 75 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“In particular, resistance to fluconazole is common [30,43,44]”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.1. Candidaemia
What the sources say
- Not checked — no full text of the sourcecites [30] Arendrup M.C. Candida and Candidaemia: Susceptibility and Epidemiology Dan. Med. J. 2013 60 1 32 24192246
- Disputedcites [43] Hii I.M. Chang H.L. Lin L.C. Lee Y.L. Liu Y.M. Liu C.E. Chen C.H. Cheng Y.R. Chang C.Y. Changing epidemiology of candidemia in a medical center in middle Taiwan J. Microbiol. Immunol. Infect. 2015 48 306 315 10.1016/j.jmii.2013.08.017 24113067 sourceExperimental — accuracy not yet measured
The Discussion reports an overall fluconazole resistance rate of 4.95% among the clinical Candida isolates, contrary to the unqualified claim that resistance is common. The Antifungal susceptibility section distinguishes resistance from reduced susceptibility: only 4.4% of C. glabrata isolates were resistant, although 66.7% were dose-dependent susceptible. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
- Supportedcites [44] Al Thaqafi A.H.O. Farahat F.M. Al Harbi M.I. Al Amri A.F.W. Perfect J.R. Predictors and outcomes of Candida bloodstream infection: Eight-year surveillance, western Saudi Arabia Int. J. Infect. Dis. 2014 21 5 9 10.1016/j.ijid.2013.12.012 24468816 source
The Discussion describes a high level of fluconazole resistance as alarming. The Results report low in vitro susceptibility among Candida bloodstream isolates in the hospital studied, supporting the claim in that setting. (LLM, conf=0.90)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Modelling with existing outcome data shows that mortality associated with these priority fungal diseases concurrently with the Joint United Nations Program on HIV/AIDS (UNAIDS) 90-90-90 campaign could save over 1.6 million lives of persons living with HIV globally over the next five years [2].”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 1. Introduction
What the sources say
- Supportedcites [2] Denning D.W. Minimizing fungal disease deaths will allow the UNAIDS target of reducing annual AIDS deaths below 500,000 by 2020 to be realized Philos. Trans. R. Soc. B 2016 371 10.1098/rstb.2015.0468 28080991 PMC5095544 source
Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The burden of infectious (all-cause, including fungal) keratitis in Mexico was estimated based on the prevalence of reported in China (0.148%) [150].”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.6. Fungal Keratitis
What the sources say
- Supportedcites [150] Cao J. Yang Y. Yang W. Wu R. Xiao X. Yuan J. Xing Y. Tan X. Prevalence of infectious keratitis in Central China BMC Ophthalmol. 2014 14 1 6 10.1186/1471-2415-14-43 24690368 PMC3976152 source
The Abstract Results report an infectious keratitis prevalence of 0.148% in Central China and separately include fungal keratitis among its causes. The Mexico estimate is the citing authors’ use of that figure, not a result attributed to this source. (LLM, conf=0.92)
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Since 2013, the Leading International Fungal Education (LIFE) portal has facilitated the estimation of the burden of serious fungal infections country by country for over 5.7 billion people (>80% of the world’s population).”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > Abstract
What the sources say
- Partly supportedcites [14] Denning D.W. Calling upon all public health mycologists Eur. J. Clin. Microbiol. Infect. Dis. 2017 36 923 924 10.1007/s10096-017-2909-8 28150046 sourceExperimental — accuracy not yet measured
The paper describes systematic country-by-country estimates of serious fungal infections and links to the LIFE site for completed estimates (p. 1). It does not state that the portal facilitated this work since 2013 or that the estimates covered over 5.7 billion people (>80% of the world’s population); its stated figure of 883 million people refers only to the current 14-country series (p. 1). (LLM, conf=0.84)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“HIV/AIDS pandemic, tuberculosis, chronic obstructive pulmonary disease (COPD), asthma and the increasing incidence of cancers are the major drivers of fungal infections in both developed and developing countries globally [1,2,3,4,5,6].”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 1. Introduction
What the sources say
- Not checked — no full text of the sourcecites [1] Brown G.D. Denning D.W. Gow N.A.R. Levitz S.M. Netea M.G. White T.C. Hidden Killers: Human Fungal Infections Sci. Transl. Med. 2012 4 1 9 10.1126/scitranslmed.3004404 23253612 source
- Partly supportedcites [2] Denning D.W. Minimizing fungal disease deaths will allow the UNAIDS target of reducing annual AIDS deaths below 500,000 by 2020 to be realized Philos. Trans. R. Soc. B 2016 371 10.1098/rstb.2015.0468 28080991 PMC5095544 sourceExperimental — accuracy not yet measured
The Introduction identifies major fungal diseases complicating HIV, and the section on chronic pulmonary aspergillosis complicating tuberculosis in HIV-positive patients names TB and COPD as underlying pulmonary disorders (page unavailable). The paper does not identify asthma or increasing cancer incidence as drivers, nor does it establish that the listed conditions are the major drivers of fungal infections globally across developed and developing countries. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [3] Armstrong-James D. Meintjes G. Brown G.D. A neglected epidemic: Fungal infections in HIV/AIDS Trends Microbiol. 2014 22 120 127 10.1016/j.tim.2014.01.001 24530175 source
- Not checked — no full text of the sourcecites [4] Guinea J. Torres-Narbona M. Gijón P. Muñoz P. Pozo F. Peláez T. de Miguel J. Bouza E. Pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: Incidence, risk factors, and outcome Clin. Microbiol. Infect. 2010 16 870 877 10.1111/j.1469-0691.2009.03015.x 19906275 source
- Not checked — no full text of the sourcecites [5] Marr K.A. Carter R.A. Boeckh M. Martin P. Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: Changes in epidemiology and risk factors Blood 2002 100 4358 4366 10.1182/blood-2002-05-1496 12393425 source
- Not checked — no full text of the sourcecites [6] Limper A.H. Adenis A. Le T. Harrison T.S. Fungal infections in HIV/AIDS Lancet Infect. Dis. 2017 10.1016/S1473-3099(17)30303-1 28774701 source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
52 more claims · 6 with their cited sources checked
Create a free account to see all 186 claims and to verify the 39 references still open.
- Probably not a substantial claim. 80
- It may state two separate claims as one. 82
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although the target organ of A. fumigatus is the lungs, Aspergillus is known to be angiotropic and has an affinity for host vasculature. As growing hyphae penetrate pulmonary tissues, they can invade the endothelial lining of nearby blood vessels and break off into circulation, causing sepsis and dissemination accompanied by thrombosis, hemorrhagic infarction and invasion of distant organs [8, 164”
From Mechanisms of fungal dissemination (2021) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Fungal pathogens are responsible for at least 13 million infections and 1.5 million deaths globally per year, primarily in those with some compromised immune function [1].”
From Prevalence and Healthcare Burden of Fungal Infections in the United States, 2018 (2022) · cites this paper as [1]
Experimental — accuracy not yet measuredIn the citing paper
“In healthy individuals, these conidia are rapidly cleared, but in the case of immunocompromised patients, conidia can germinate and develop filamentous hyphae [1, 166]. This fungal growth can result in invasive aspergillosis: a severe and aggressive fungal disease characterized by tissue damage, necrosis and hypoxia [8, 164, 167].”
From Mechanisms of fungal dissemination (2021) · cites this paper as [8]
In the citing paper
“Candida albicans the primary species responsible for mucosal disease”
From Acquisition of cross-azole tolerance and aneuploidy in Candida albicans strains evolved to posaconazole (2022) · cites this paper as Bongomin et al. 2017
In the citing paper
“Deep-seated candidiasis, arising from direct inoculation or hematogenous dissemination of Candida into normally sterile body sites, is often difficult to diagnose and may affect a population as large as that of candidemia [4,5,6].”
From Treatment of Invasive Candidiasis: A Narrative Review (2018) · cites this paper as [4]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.5. Allergic Bronchopulmonary Aspergillosis (ABPA) & Severe Asthma with Fungal Sensitisation (SAFS)
“28,447 [2.5% of 1,136,092] (62 per 100,000) patients with ABPA”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.5. Allergic Bronchopulmonary Aspergillosis (ABPA) & Severe Asthma with Fungal Sensitisation (SAFS)
“37,491 [3.33% of 1,136,092] (37.5 per 100,000) with severe asthma with fungal sensitisation (SAFS)”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.5. Allergic Bronchopulmonary Aspergillosis (ABPA) & Severe Asthma with Fungal Sensitisation (SAFS)
“Average incidence is 154 cases per 100,000 (SD ± 654)”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.5. Allergic Bronchopulmonary Aspergillosis (ABPA) & Severe Asthma with Fungal Sensitisation (SAFS)
“the highest incidence rates reported in United Kingdom (654 per 100,000)”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.1. Candidaemia
“The total burden of candidaemia is 159,253 cases across these 39 countries with available data.”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.1. Candidaemia
“Europe (n = 1 country, 420,549 cases)”
Citations
Cites
Vos, T., Flaxman, A. D., Naghavi, M., Lozano, R., Michaud, C., Ezzati, M., Shibuya, K., Salomon, J. A., Abdalla, S., Aboyans, V., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61729-2 · Cited by 8,291
Wang, H., Naghavi, M., Allen, C., Barber, R. M., Bhutta, Z. A., Carter, A., Casey, D. C., Charlson, F. J., Chen, A. Z., Coates, M. M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31012-1 · Cited by 6,596
Wisplinghoff, H., Bischoff, T., Tallent, S. M., Seifert, H., Wenzel, R. P., & Edmond, M. B. (2004) · Clinical Infectious Diseases · doi:10.1086/421946 · Cited by 4,496 · cited 1×
“Candidaemia is the most common form of invasive candidiasis associated with an unacceptably high mortality rates in excess of 40% even with the introduction of newer antifungal agents [30,32,33].”
BackgroundHidden Killers: Human Fungal Infections
Brown, G. D., Denning, D. W., Gow, N. A. R., Levitz, S. M., Netea, M. G., & White, T. C. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004404 · Cited by 4,284 · cited 1×
“Pneumocystis jirovecii pneumonia is emerging as a leading cause of infection in HIV/AIDS patients [1].”
BackgroundSelf-citationGlobal burden of disease of HIV-associated cryptococcal meningitis: an updated analysis
Rajasingham, R., Smith, R. M., Park, B. J., Jarvis, J. N., Govender, N. P., Chiller, T. M., Denning, D. W., Loyse, A., & Boulware, D. R. (2017) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30243-8 · Cited by 1,861 · cited 1×
“[8], Fungal Infection Trust [12], Global Action Fund for Fungal Infection (GAFFI) Roadmap [9], and van de Sande [13].”
BackgroundSelf-citationGlobal asthma prevalence in adults: findings from the cross-sectional world health survey
To, T., Stanojevic, S., Moores, G., Gershon, A. S., Bateman, E. D., Cruz, A. A., & Boulet, L.-P. (2012) · BMC Public Health · doi:10.1186/1471-2458-12-204 · Cited by 1,521 · cited 1×
“6% respectively among individuals aged 18 to 45 years [142].”
BackgroundKullberg, B. J., & Arendrup, M. C. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1315399 · Cited by 1,315 · cited 1×
“Candidaemia is the most common form of invasive candidiasis associated with an unacceptably high mortality rates in excess of 40% even with the introduction of newer antifungal agents [30,32,33].”
BackgroundSobel, J. D. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60917-9 · Cited by 1,270
Marr, K. A., Carter, R. A., Boeckh, M., Martin, P., & Corey, L. (2002) · Blood · doi:10.1182/blood-2002-05-1496 · Cited by 957
(2006) · PubMed · Cited by 906
Research works printed but not linked: 6
- Denning D.W. Global fungal Burden Mycoses 2013 56 13
- The Fungal Infection Trust How common are fungal diseases? Proceedings of the Fungal Research Trust 20th Anniversary Meeting London, UK 18 June 2011 updated August 2017, London, UK 2017 Available online: http://www.fungalinfectiontrust.org/wp-content/uploads/2015/12/How-Common-are-Fungal-Diseases-v12.2.pdf (accessed on 12 September 2017)
- Jayasekera P.I. Denning D. Perera P. Fernando A. Kudavidanage S. The burden of serious fungal infections in Sri Lanka Mycoses 2013 56 103
- Beardsley J. Denning D. Chau N. Crump J. Day J. Estimating the burden of fungal diseases in Vietnam Eur. Conf. Clin. Microbiol. Infect. Dis. Published Online First: 2014 Available online: http://eccmid.meetingxpert.net/ECCMID_699/poster_108496/program.aspx/anchor108496 (accessed on 31 August 2017)
- Gugnani H.C. Denning D.W. Rahim R. Sadat A. Belal M. Mahbub M.S. Medina N. Samayoa B. Lau-Bonilla D. Denning D.W. Burden of serious fungal infections in Bangladesh Eur. J. Clin. Microbiol. Infect. Dis. 2017 36 965 969 10.1007/s10096-017-2921-z 28161744 · DOI · Paper page
- Samayoa B. Isern V. Serra L. Rivera B.E. Nikiforov M. Arathoon E. Samayoa C. Vallès X. Prieto L. Álvarez C. Preliminary results of a prospective cohort of HIV+ patients in Guatemala Proceedings of the XVIII International AIDS Conference Vienna, Austria 18–23 July 2010
Cited by
Items 2,201–2,300 of 2,932
Alcántara-Mojica, A., Delhaès, L., Ramírez‐Corona, F., et al. (2020) · Gaceta Médica de México · doi:10.24875/gmm.m19000301 · Cited by 1
Candida, the Opportunistic Human Pathogen
Shahabudin, S., & Azmi, N. S. (2020) · Materials science forum · doi:10.4028/www.scientific.net/msf.981.309 · Cited by 2
“Fungal infections are caused by many types of pathogenic fungi and affect 80% of the world population [1].”
BackgroundFungal Infection: The Hidden Enemy?
Oves, M., Rauf, M. A., Husain, F. M., Zubair, M., Ismail, I. M. I., & Iyer, A. K. (2020) · Springer eBooks · doi:10.1007/978-981-15-7639-3_10 · Cited by 1
Blindness from Fungal Rhinosinusitis of the Paranasal Sinuses: A Case Report
Jesus, D. R. D., & Estolano, P. J. (2020) · Philippine Journal of Otolaryngology Head and Neck Surgery · doi:10.32412/pjohns.v35i2.1515 · Cited by 1
Invasive Candidiasis in Surgical Patients
Sganga, G., Fransvea, P., Pepe, G., Grezia, M. D., & Cozza, V. (2021) · Hot topics in acute care surgery and trauma · doi:10.1007/978-3-030-62116-2_20 · Cited by 1
The first case of Trichophyton spp. pneumonia reported in Vietnam
Le-Thuong, V., Đức, N. M., My, T. T., Bang, L. V., Luu, D. T., & Thông, P. M. (2021) · Respiratory Medicine Case Reports · doi:10.1016/j.rmcr.2021.101371 · Cited by 3
“Recent years have witnessed an escalation in the incidence of fungal infections worldwide [1].”
BackgroundCurrent Promising Therapeutic Targets for Aspergillosis Treatment
Srivastava, S., Maurya, N. S., Kushwah, S., & Mani, A. (2021) · Journal of Pure and Applied Microbiology · doi:10.22207/jpam.15.2.09 · Cited by 2
“(2)Both human and fungi shares basic eukaryotic characteristics,so target or inhibitors should provide favourable therapeutictoxic ratio.(3)Target of fungal pathogen is widely spread and it should be economically attractive7.”
BackgroundPrédisposition génétique aux infections fongiques cutanéomuqueuses
Baghad, B., Bousfiha, A. A., Chiheb, S., & Ailal, F. (2021) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2021.05.009 · Cited by 4
Battu, A., Purushotham, R., & Kaur, R. (2021) · BIO-PROTOCOL · doi:10.21769/bioprotoc.4210 · Cited by 1
Application of Neural Networks to a Constrained Multifacility Location Problem.
Santra, A. K., & Nasira, G. M. (2007) · Artificial Intelligence and Pattern Recognition · Cited by 1
Resolving molecular orientation by polarization-sensitive stimulated Raman scattering microscopy
Dong, P., Zong, C., & Cheng, J. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-85158-9.00025-7 · Cited by 2
Parinyarux, P., Thavornwattanayong, W., Soontornpas, C., & Rawangnam, P. (2022) · Pharmacy · doi:10.3390/pharmacy10010029 · Cited by 1
“Superficial fungal infections (SFIs) are among the most common skin diseases worldwide, affecting nearly one billion people annually [1].”
BackgroundA structural model of the human plasminogen and Aspergillus fumigatus enolase complex
Nguyen, S. A., Jovcevski, B., Truong, J. Q., Pukala, T. L., & Bruning, J. B. (2022) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.26331 · Cited by 3
A New Natural Antimycotic Agent is Effective Against Oropharyngeal Candidiasis: The VIPROCAN Study
Carrión-Navarro, J., Argüelles, A., Martínez‐Gimeno, M. L., Lozada, A. T., Ayuso‐Sacido, Á., Belda-Iniesta, C., Arnás-Rodríguez, M., & Garcia‐Romero, N. (2022) · The Open Dentistry Journal · doi:10.2174/18742106-v16-e2202010 · Cited by 1
Climate Change and Global Distribution of Cryptococcosis
Sánchez-Paredes, E., León, Y. P. A., Alvarado-Ramírez, E., Castañón-Olivares, L. R., & Aguilar, M. L. M. (2022) · Fungal biology · doi:10.1007/978-3-030-89664-5_11 · Cited by 1
Azar, M. M. (2019) · Springer eBooks · doi:10.1007/978-3-030-25553-4_11 · Cited by 2
Effectiveness of Coconut (Cocos nucifera) Extracts as an Inhibitor Against Aspergillosis
Olugbenga, A., Usman, N. G., & Olukotun, G. B. (2022) · Advanced Journal of Graduate Research · doi:10.21467/ajgr.12.1.48-54 · Cited by 1
“Aspergillosis is thought to affect more than 14 million people worldwide, [9] with Allergic Broncho-Pulmonary Aspergillosis (ABPA, >4 million), severe asthma with fungal sensitization (>6.”
BackgroundZhang, T., Wang, Y., Qi, J., et al. (2022) · Aerobiologia · doi:10.1007/s10453-022-09747-6 · Cited by 1
“6 million people die from fungal infections every year (Bongomin et al. 2017).”
BackgroundApplication of natural products against fungal biofilm formation
Samreen, S., Jafri, H., & Ahmad, I. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-88480-8.00017-0 · Cited by 1
Antifungal and Antibiofilm Activities of Some Essential Oils Against Candida spp
Atron, B., AHAMADA, H., Kafa, A. H. T., Çelik, C., & Hasbek, M. (2022) · Cumhuriyet Science Journal · doi:10.17776/csj.1102028 · Cited by 2
Wang, X., Wang, X., Cai, T., Qin, Y., Li, L., Jiang, Y., Han, B., & Cao, Y.-B. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.1007576 · Cited by 3
“Systemic candidiasis is a serious healthcare-associated infection in Europe and US, and associated with high mortality rates (40%) among hospitalized patients, particularly in individuals with hematological malignancies, undergoing major surgery, cytotoxic chemotherapy, and organ transplantation (Magill et al., 2014;…”
BackgroundPathan, S. K., Sangshetti, J. N., & Patil, R. (2022) · Bulletin of Pharmaceutical Sciences Assiut · doi:10.21608/bfsa.2022.271592 · Cited by 1
A incidência de doenças causada por leveduras Cândida albicans, glabrata e tropicalis
Souza, J. D. S., Morais, K. S. D., Barros, N. B. D., & Barros, R. R. (2022) · Brazilian Journal of Development · doi:10.34117/bjdv8n11-374 · Cited by 7
Legaspi, C. L. (2020) · Pediatric Infectious Disease Society of the Philippines Journal · doi:10.56964/pidspj20202102008 · Cited by 1
Breaking the mould, a first parse at natural language processing in aspergillosis diagnosis
Pates, K. M., Shang, Z., Periselneris, J. N., & Shah, A. (2023) · Journal of Thoracic Disease · doi:10.21037/jtd-22-1393 · Cited by 2
“J Thorac Dis 2023;15(1):17-21 | https://dx.”
BackgroundSan-Quirico, E., Curto, M.-Á., Gómez-Delgado, L., Moreno, M. B., Pérez, P., Ribas, J. C., & Cortés, J. C. G. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054299 · Cited by 2
“Patients in intensive care units, those undergoing invasive medical practices and being treated with broad-spectrum antibiotics, and those undergoing organ transplantation and receiving immunosuppressant drugs are also at great risk [1,3,4].”
BackgroundFeys, S., Dedeurwaerdere, F., Lagrou, K., Lerbeirghe, J. V., & Deeren, D. (2023) · Journal of Fungi · doi:10.3390/jof9030327 · Cited by 2
“Introduction Invasive aspergillosis is one of the most frequent invasive fungal infections, with an estimated annual incidence of approximately 250,000 cases each year [1].”
BackgroundCandidaemia in Neonatal Intensive Care Units (NICU) at Beni-Suef Governorate
Radi, N., Mabrook, A., Tohamy, M., & Abdel-Aziz, M. (2023) · The Egyptian Journal of Medical Microbiology · doi:10.21608/ejmm.2023.293577 · Cited by 1
Ovarian aspergilloma in an immunocompetent patient masquerading as ovarian neoplasm
Singh, G., Singh, A. K., & Verma, A. (2023) · Archive of Clinical Cases · doi:10.22551/2023.38.1001.10237 · Cited by 1
“Because of varying clinical manifestations, often of a severe nature-Aspergillosis remains a major cause of patient morbidity and is responsible for more than one million mortalities in immunocompromised populations worldwide, annually [4].”
BackgroundPathoproteomik des humanpathogenen Pilzes Aspergillus fumigatus
Bigalke, A., Krüger, T., Jia, L., Kniemeyer, O., & Brakhage, A. A. (2023) · BIOspektrum · doi:10.1007/s12268-023-1932-9 · Cited by 1
“Sci Transl Med 4: 165rv13 [2] Bongomin F, Gago S, Oladele RO et al.”
BackgroundMoon, J. Y., Suh, W., Jun, R. M., & Han, K. E. (2023) · Cutaneous and Ocular Toxicology · doi:10.1080/15569527.2023.2226714 · Cited by 2
Huang, J.-J., Zhang, S.-S., Liu, M., Yang, E.-Y., Pan, Y., & Wu, J. (2023) · World Journal of Clinical Cases · doi:10.12998/wjcc.v11.i18.4425 · Cited by 2
Introduction: Metal Complexes as Therapeutic Agents
Hussain, A., Alajmi, M. F., Lone, M. A., & Wani, W. A. (2023) · Springer briefs in molecular science · doi:10.1007/978-3-031-35631-5_1 · Cited by 3
Draft genomes of Aspergillus nomiae and Aspergillus tamarii isolates from human eye infections
Hatmaker, E. A., Schmitz, J. E., & Rokas, A. (2023) · Microbiology Resource Announcements · doi:10.1128/mra.00391-23 · Cited by 1
“At least a million new FK cases are reported annually worldwide (4).”
BackgroundLe, T. P. (2023) · Elsevier eBooks · doi:10.1016/b978-0-7020-7959-7.00045-2 · Cited by 1
A clinicoepidemiological study of geriatric dermatoses
Eslavat, S., Vemu, D., Kunti, S., Prasad Naik, N. M., & Ramadas, K. (2023) · EUREKA Health Sciences · doi:10.21303/2504-5679.2023.003007 · Cited by 1
Nurcahyanti, A. D. R., Liliana, M., & Surja, S. S. (2023) · Journal of Applied Pharmaceutical Science · doi:10.7324/japs.2023.152976 · Cited by 2
N-acetylglucosamine: a behavioral fate switch in Candida albicans
Mondal, D., & Thakur, J. K. (2023) · Trends in Microbiology · doi:10.1016/j.tim.2023.08.014 · Cited by 1
Evolutionary diversity of the control of the azole response by Tra1 across yeast species
Marsiglio-Librais, G. N., Jiang, Y., Razzaq, I., Brandl, C. J., Shapiro, R. S., & Lajoie, P. (2023) · G3 Genes Genomes Genetics · doi:10.1093/g3journal/jkad250 · Cited by 1
“Fungal infections represent a major public health concern with over a billion infections each year resulting in more than 1.5 million deaths (Bongomin et al. 2017).”
BackgroundInfluentialWarella, J. C., Rahma, K., Widodo, A. D. W., & Setiabudi, R. J. (2023) · Folia Medica Indonesiana · doi:10.20473/fmi.v59i3.44165 · Cited by 7
Lacombe, C., Alemán-Navarro, E., Drujon, T., Martinez-Osorio, V., Sachon, E., Melchy-Pérez, E., Carlier, L., Brigido, L. E. F., Fleury, Y., Piesse, C., et al. (2024) · International Journal of Inflammation · doi:10.1155/2024/2205864 · Cited by 4
“…the potential of DRS-DA2N and DRS-DA2NEQ to function as anti-microbial agents, we tested the antifungal activity of DRS-DA2N and DRS-DA2NEQ on C. glabrata CBS138 and C. albicans SC5314, two strains responsible for most bloodstream infections worldwide, associated with high mortality rates [23].”
BackgroundPandya, H. B., Bhad, K., Patel, V. R., et al. (2023) · Annals of Maxillofacial Surgery · doi:10.4103/ams.ams_79_23 · Cited by 1
Thamnostylum piriforme, a novel etiological agent of superficial mycosis
Sharma, B., & Nonzom, S. (2024) · Microbial Pathogenesis · doi:10.1016/j.micpath.2024.106544 · Cited by 1
A Rare Case of Fungal Osteomyelitis of the Distal Tibia in a Pediatric Patient
Afaque, S. F., Agrawal, U., Shankhwar, D. K., et al. (2024) · Cureus · doi:10.7759/cureus.54648 · Cited by 1
“Over 100,000 fungal species have been described; only 150 are pathogenic to humans [5].”
BackgroundKhan, Z., Ahmad, S., & Asadzadeh, M. (2024) · Clinical and Experimental Obstetrics & Gynecology · doi:10.31083/j.ceog5102039 · Cited by 1
“The global incidence of mucocutaneous and invasive fungal infections have increased in the last two decades due to an expanding population of susceptible patients, and increasing use of antifungal prophylaxis [1–6].”
BackgroundDiversity and Distribution Patterns of Culturable Airborne Fungi in Jiroft City
Kamali, M., & Sarvtin, M. T. (2024) · International Journal of Medical Laboratory · doi:10.18502/ijml.v10i4.15008 · Cited by 1
Girma, A. (2024) · JOURNAL OF COMMUNICABLE DISEASES · doi:10.24321/0019.5138.202360 · Cited by 1
Joshi, M., Singh, A. P., Gupta, P., & Bansal, H. (2024) · International Journal for Research in Applied Science and Engineering Technology · doi:10.22214/ijraset.2024.60355 · Cited by 3
Maslov, O. Y., Komisarenko, M. A., Ponomarenko, S. V., et al. (2024) · European Pharmaceutical Journal · doi:10.2478/afpuc-2024-0006 · Cited by 1
Aspergillus-assoziierte Erkrankungen aus infektiologischer und allergologischer Perspektive
Stemler, J., Nacov, J. A., Sprute, R., Cornely, O. A., Joest, M., Becker, S., & Klimek, L. (2024) · Allergo Journal · doi:10.1007/s15007-024-6283-4 · Cited by 1
Fungal Infection in Upper Gastrointestinal Tract
Lee, A., Jung, S. W., & Kim, J. M. (2024) · The Korean Journal of Helicobacter and Upper Gastrointestinal Research · doi:10.7704/kjhugr.2024.0029 · Cited by 1
Peng, J., Li, R., Li, Z., et al. (2024) · European Journal of Organic Chemistry · doi:10.1002/ejoc.202400400 · Cited by 1
Comparative study of Candidiasis among Single and Married women at Rwanda Military Hospital
Chrysostome, U. J., PRUDENCE, I. A., Innocent, N., Pierre, U. J., Ezechiel, B., Fabrice, U., Julienne, M., de Dieu, N. J., & Pacifique, M. (2024) · Journal of Drug Delivery and Therapeutics · doi:10.22270/jddt.v14i6.6652 · Cited by 1
Sharma, G., & Sharma, R. K. (2024) · Biomeditsinskaya Khimiya · doi:10.18097/pbmc20247003180 · Cited by 1
Maslov, O. Y., Komisarenko, M. A., Ponomarenko, S. V., et al. (2024) · Current issues in pharmacy and medicine science and practice · doi:10.14739/2409-2932.2024.2.300967 · Cited by 1
“In infectious diseases, an excess of free radicals occurs as a result of pathophysiological and biochemical processes caused by the effects of pathogenic bacteria and fungi on human cells [ 5].”
BackgroundPandey, S., & Mehta, D. M. (2024) · International Journal of Pharmaceutical Sciences and Drug Research · doi:10.25004/ijpsdr.2024.160111
Jaquelin, N.-B., Romero-Romero, D., Contreras-Rodríguez, A., Aguilera‐Arreola, M. G., & Parra-Ortega, B. (2024) · Archives of Medical Research · doi:10.1016/j.arcmed.2024.103038 · Cited by 2
Kumar, M., Kajal, K., Taranum, N., Khyati, Balan, B., Kumar, P., & Dhaulaniya, A. S. (2024) · Springer eBooks · doi:10.1007/978-981-97-5165-5_22 · Cited by 2
Kaur, H., & Wadhwa, K. (2024) · Springer eBooks · doi:10.1007/978-981-97-5165-5_12 · Cited by 1
Palanivel, J., Mohapatra, M. M., Rajaram, M., Gochhait, D., Chakkalakkoombil, S. V., & Singh, R. (2024) · Monaldi Archives for Chest Disease · doi:10.4081/monaldi.2024.3041 · Cited by 3
“Various risk factors for AE-COPD have been proposed, with a history of prior exacerbation emerging as the single most reliable predictor [18].”
BackgroundUnravelling novel molecular targets of Thymol and Carvacrol in Candida glabrata
Kumar, D., Ansari, A., Rai, N., & Kumar, N. (2024) · Environment Conservation Journal · doi:10.36953/ecj.27792845 · Cited by 1
“The prevalence and variety of Candida infections have undergone significant changes in recent decades, resulting in a global increase in candidiasis incidence that now exceeds 43 - 75% (Bongomin et al. , 2017; Diseases 2018; Sharma et al. , 2023).”
BackgroundWu, J., Yu, J., Li, H., Wang, Y., & Xu, R. (2024) · Medicine · doi:10.1097/md.0000000000040103 · Cited by 1
“[3] In patients with liver failure, immunosuppression, intestinal flora disturbance, repeated hospitalization, malnutrition, mucosal barrier destruction, and long-term use of broad-spectrum antibiotics, among other factors, can cause secondary infections.”
BackgroundFungi that are medically relevant to humans and their prospect in a global warming scenario
Franco, B., Vargas-Maya, N. I., Padilla‐Vaca, F., Montiel, F. B. R., & Martínez-Álvarez, J. A. (2024) · Academia molecular biology and genomics. · doi:10.20935/acadmolbiogen7400 · Cited by 2
Az orrmelléküregek mucormycosisa
Iszlai, Z., Kiss-Tóth, E., & Karosi, T. (2024) · Orvosi Hetilap · doi:10.1556/650.2024.33167 · Cited by 1
SUMO-targeted Ubiquitin Ligases as crucial mediators of protein homeostasis in Candida glabrata
Gupta, D., Shukla, R., & Mishra, K. (2024) · PLoS Pathogens · doi:10.1371/journal.ppat.1012742 · Cited by 1
Fu, T.-J., Lin, S. R., Wang, T., Chou, K., & Huang, S. (2024) · Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC) · doi:10.1109/embc53108.2024.10781884 · Cited by 3
“With advancements in diagnostic techniques in recent years, the incidence and high mortality rate of CPA have been increasingly recognized [2][3].”
Wei, K., Arlotto, M., Overhulse, J. M., Dinh, T., Zhou, Y., Dupper, N. J., Yang, J., Kashemirov, B. A., Dawi, H., Garnaud, C., et al. (2025) · Advanced Science · doi:10.1002/advs.202404260 · Cited by 2
Sachdev, J., Gourav, S., Xess, I., Soneja, M., Punjadath, S., Siddharth, V., Pandey, M., Gupta, S., Manhas, A., Rana, B., et al. (2025) · Medical Mycology · doi:10.1093/mmy/myaf003 · Cited by 1
Polianska, V. P., Bezega, M. I., Zachepylo, S. V., & Звягольська, І. М. (2024) · Clinical and Preventive Medicine · doi:10.31612/2616-4868.8.2024.09 · Cited by 2
“Almost a billion people worldwide suffer from fungal infections, the severity of which varies from asymptomatic and mild to potentially life-threatening conditions [1].”
Das, M., Albert, V., Sharma, S., Singh, G., Hallur, V., Pamidimukkala, U., Singh, K. J., Karuna, T., Xess, I., Savio, J., et al. (2025) · Infectious diseases · doi:10.5772/intechopen.1009310 · Cited by 2
Meier, C. S., Pagni, M., Richard, S., Mühlethaler, K., & Hauser, P. M. (2025) · mBio · doi:10.1128/mbio.00692-25 · Cited by 1
“approximately half a million cases reported annually worldwide (2).”
Fungal immunization potentiates CD4+ T cell-independent cDC2 responses for cross-presentation
Kulkarni, N. A., & Nanjappa, S. G. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1602174 · Cited by 2
The Role of Gram Stain in Differentiating Superficial Cutaneous Fungal Organisms
Nolff, T. M., Pedersen, L. D., Watts, L. Y. A., et al. (2025) · Journal of Cutaneous Pathology · doi:10.1111/cup.14827 · Cited by 1
“Candida spp., dermatophytes, and Malassezia spp. are the most common pathogens with varying clinical presentations [2–4].”
Pérez-García, G., Cruz, N. S., Carrasco, Z. D. C., Lázaro-Rodríguez, V., Weingartshofer, R. D., Arnal, M. A. G., García, A. M., de Nadal, M. C., & Giménez, I. L. (2025) · Journal Français d Ophtalmologie · doi:10.1016/j.jfo.2025.104576 · Cited by 1
Vogel, T., Yu, Y., Keller, T., et al. (2025) · Drug Discoveries & Therapeutics · doi:10.5582/ddt.2025.01041 · Cited by 1
Wong, S. S. W., Dellière, S., Lepas, M., & Aimanianda, V. (2025) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-85340-1_9 · Cited by 2
Li, Z., Li, F., Chen, T., & Yang, R. (2025) · Infection and Drug Resistance · doi:10.2147/idr.s519105 · Cited by 2
Guo, Y., Zhu, L., & Li, H. (2025) · The Journal of Immunology · doi:10.1093/jimmun/vkaf071 · Cited by 2
Garg, P., Singh, N. R., Liu, A. J., Yong, M. K., Slavin, M. A., Hall, L., & Worth, L. J. (2025) · BMJ Open · doi:10.1136/bmjopen-2025-100798 · Cited by 2
“Key OIs for the study been defined for the purposes of this study as immunocompromised host relevant infections with modifiable risk factors (vaccination or prophylaxis), or for which laboratory screening methods are routinely available and regularly utilised prior to commencing immunosuppressive…”
de Oliveira, R. D., de Alencar, R. R. F. R., António, B. V. R., Leal, P. C., Franco, E. D. S., & dos Santos, L. M. (2019) · Dermatology Online Journal · doi:10.5070/d3258045127 · Cited by 1
“Recent global estimates have found more than 100,000 cases of disseminated histoplasmosis, a serious fungal infection that occurs as a consequence of certain health problems, such as HIV-AIDS [6].”
BackgroundMycoses in Intensive Care Units
Todi, S. K. (2019) · Springer eBooks · doi:10.1007/978-981-13-9459-1_5 · Cited by 1
Challenges, Pitfalls, and Possible Solution for Asian Countries
Soman, R. N., & Sunavala, A. (2019) · Springer eBooks · doi:10.1007/978-981-13-9459-1_21 · Cited by 1
Tevyashova, A. N., Бычкова, Е. Н., Solov’eva, S. E., Grammatikova, N. E., & Shchekotikhin, A. E. (2020) · Pharmaceutical Chemistry Journal · doi:10.1007/s11094-020-02108-y · Cited by 1
Diagnosis of Invasive Fungal Infections: Culture and Antifungal Susceptibility Tests
Doğan, Ö. (2020) · Klimik Dergisi/Klimik Journal · doi:10.5152/kd.2019.55 · Cited by 1
Detección de hongos y aflatoxinas en alimentos de importancia en salud pública
Rojas‐Jaimes, J. (2019) · Diagnóstico · doi:10.33734/diagnostico.v58i2.11 · Cited by 1
Gugnani, H. C. C. (2018) · Journal of Infectiology · doi:10.29245/2689-9981/2018/2.1112 · Cited by 1
Diagnostic des mycoses profondes et apport des méthodes complémentaires en pathologie
Hofman, P. M. (2020) · Revue Francophone des Laboratoires · doi:10.1016/s1773-035x(20)30028-9 · Cited by 1
Villalobos, A. P. C., & Husain, S. (2020) · Springer eBooks · doi:10.1007/978-3-030-01751-4_44-1 · Cited by 1
Kakhki, R. K., Najafzadeh, M. J., Kachuei, R., & Ghazvini, K. (2020) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-020-03879-8 · Cited by 2
Alexander, A. J. T., Muñoz, A., Marcos, J. F., & Read, N. D. (2020) · Molecular Microbiology · doi:10.1111/mmi.14532 · Cited by 1
“Fungi collectively kill over 1.5 million people annually which is more than malaria and similar to the death toll from tuberculosis (Brown et al., 2012; Bongomin et al., 2017).”
BackgroundInfluentialNguyen, M.-V. H., Wiederhold, N. P., Cañete-Gibas, C. F., Sanders, C. J., & Thompson, G. R. (2020) · Journal of Clinical Microbiology · doi:10.1128/jcm.01325-20 · Cited by 1
Hidayat, F. R., Sukiman, S., Hidayati, E., Sarkono, S., Suryadi, B. F., & Faturrahman, F. (2020) · Journal of Science and Science Education · doi:10.29303/jossed.v1i1.453 · Cited by 1
“Fungal severe infections occur due to other health problems, including asthma, AIDS, cancer, organ transplants, and corticosteroid therapy [1]; [2].”
BackgroundProtective immune studies against fungi
KUMONDOROVA, A., & Metiner, K. (2020) · Journal of Istanbul Veterinary Sciences · doi:10.30704/http-www-jivs-net.778761 · Cited by 2
“Continuous exposure of humans and animals to both commensal and environmental fungi require a strong immune system for tolerance and protection while limiting collateral damage caused by excessive or harmful inflammations has been reported by researchers (Bongomin et al., 2017).”
BackgroundAutomated Quantitative Analysis of Airway Epithelial Cell Detachment Upon Fungal Challenge
Rahman, S., Thomson, D. D., & Bertuzzi, M. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1182-1_16 · Cited by 1
Genital Tract Infection during Pregnancy and its Association with Preterm Delivery
Susilawati, T. N., & Satria, Y. A. A. (2021) · Indonesian Journal of Tropical and Infectious Disease · doi:10.20473/ijtid.v8i3.11460 · Cited by 1
Çolak, M. Y., & Aşgın, N. (2021) · Journal of Surgery and Medicine · doi:10.28982/josam.910783 · Cited by 1
“These species are primarily intrinsic and acquired resistance to azoles and echinocandins, agents used in the prophylaxis and treatment of Candida infections [11,19,20].”
BackgroundCyberlindnera fabianii: primer aislamiento clínico en Chile
Álvarez, E., & Cepeda, N. (2021) · Revista Iberoamericana de Micología · doi:10.1016/j.riam.2021.04.009 · Cited by 1
Kutsevalova, O. Y., Kozel, Y. Y., Nifantiev, N. E., Antonets, A. V., & Krylov, V. B. (2021) · South Russian Journal of Cancer · doi:10.37748/2686-9039-2021-2-3-5 · Cited by 1
“В странах Европы, данный показатель варьируется от 2,2 до 11 на 100 тысяч населения [4].”
Mycotic Diseases (Aspergillosis)
Malik, Y. S., Milton, A. A. P., Ghatak, S., & Ghosh, S. (2021) · Livestock diseases and management · doi:10.1007/978-981-16-4554-9_20 · Cited by 3
Savi, G. D., Bortolotto, T., Costa, F. V., Rabelo, B. D., Negro‐Dellacqua, M., & de Sousa, I. F. (2022) · Research Society and Development · doi:10.33448/rsd-v11i1.25237 · Cited by 1
Metadata
- Authors
- Bongomin, F., Gago, S., Oladele, R., & Denning, D.
- Affiliations
- University of Manchester (GB)
- Corresponding author
- Denning, David
- Venue
- Journal of Fungi
- Publisher
- MDPI AG
- Published
- 2017-10-18
- Volume
- 3
- Issue
- 4
- Pages
- 57
- ISSN
- 2309-608X (ISSN-L)
- PMC
- PMC5753159
- OpenAlex
- W2767031614
- Semantic Scholar
- a31bc4c8c2356520b0818d41b5c4a2e2091b6f32
- Cited by
- 2,953
- References
- 192
- Citations by year
- 2026: 280 · 2025: 388 · 2024: 518 · 2023: 436 · 2022: 427 · 2021: 370 · 2020: 307 · 2019: 156 · 2018: 67 · 2017: 2
- FWCI
- 22.27
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Fungi (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Research Explorer (The University of Manchester) (publishedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC/P002390/1)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Health Sciences › Medicine › Dermatology › Nail Diseases and Treatments
- Keywords
- fungal infection, disease burden estimation, prevalence, chronic pulmonary aspergillosis, cryptococcal meningitis, invasive candidiasis, Pneumocystis carinii pneumonia, invasive aspergillosis, disseminated histoplasmosis, fungal asthma, fungal keratitis, HIV/AIDS, antifungal therapy, estimation accuracy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.